Similar articles for PMID: 32096619

Year	Number of Results
1993	1
1994	1
1996	1
1997	3
1998	2
1999	2
2000	5
2001	2
2002	2
2003	2
2004	3
2005	5
2006	9
2007	8
2008	8
2009	4
2010	3
2011	4
2012	4
2013	3
2014	6
2015	5
2016	4
2017	4
2018	5
2019	4
2020	8
2022	1
2024	0

1

Mu-opioid antagonism in the treatment of cannabis use disorder.

Kebir O, Laqueille X, Mouaffak F. Kebir O, et al. J Psychiatry Neurosci. 2020 Mar 1;45(2):143. doi: 10.1503/jpn.190182. J Psychiatry Neurosci. 2020. PMID: 32096619 Free PMC article. No abstract available.

2

Use of naltrexone in ketamine dependence.

Garg A, Sinha P, Kumar P, Prakash O. Garg A, et al. Addict Behav. 2014 Aug;39(8):1215-6. doi: 10.1016/j.addbeh.2014.04.004. Epub 2014 Apr 13. Addict Behav. 2014. PMID: 24813545

3

Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.

Hermes G, Hyman SM, Fogelman N, Kosten TR, Sinha R. Hermes G, et al. Am J Addict. 2019 Nov;28(6):480-488. doi: 10.1111/ajad.12942. Epub 2019 Aug 26. Am J Addict. 2019. PMID: 31448846 Clinical Trial.

4

Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects.

Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME. Weerts EM, et al. Neuropsychopharmacology. 2008 Feb;33(3):653-65. doi: 10.1038/sj.npp.1301440. Epub 2007 May 9. Neuropsychopharmacology. 2008. PMID: 17487229

5

Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.

Ko MC, Divin MF, Lee H, Woods JH, Traynor JR. Ko MC, et al. J Pharmacol Exp Ther. 2006 Feb;316(2):772-9. doi: 10.1124/jpet.105.094409. Epub 2005 Oct 28. J Pharmacol Exp Ther. 2006. PMID: 16258020

6

Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Weerts EM, Wand GS, Kuwabara H, Xu X, Frost JJ, Wong DF, McCaul ME. Weerts EM, et al. Addict Biol. 2014 Jul;19(4):733-42. doi: 10.1111/adb.12022. Epub 2012 Dec 18. Addict Biol. 2014. PMID: 23252742 Free PMC article.

7

Medications development for opioid abuse.

Negus SS, Banks ML. Negus SS, et al. Cold Spring Harb Perspect Med. 2013 Jan 1;3(1):a012104. doi: 10.1101/cshperspect.a012104. Cold Spring Harb Perspect Med. 2013. PMID: 23125072 Free PMC article. Review.

8

The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.

Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA. Mannelli P, et al. Am J Drug Alcohol Abuse. 2012 May;38(3):200-5. doi: 10.3109/00952990.2011.644003. Epub 2012 Jan 10. Am J Drug Alcohol Abuse. 2012. PMID: 22233189 Free PMC article. Clinical Trial.

9

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Mannelli P, Peindl K, Patkar AA, Wu LT, Pae CU, Gorelick DA. Mannelli P, et al. J Clin Psychopharmacol. 2010 Aug;30(4):476-8. doi: 10.1097/JCP.0b013e3181e5c168. J Clin Psychopharmacol. 2010. PMID: 20631574 Free PMC article. No abstract available.

10

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.

Sadee W, Oberdick J, Wang Z. Sadee W, et al. Molecules. 2020 Sep 11;25(18):4163. doi: 10.3390/molecules25184163. Molecules. 2020. PMID: 32932935 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year